SCMOM 2012_The Clinical Outlook for Regenerative Medicine – Video

Posted: Published on November 29th, 2012

This post was added by Dr P. Richardson




SCMOM 2012_The Clinical Outlook for Regenerative Medicine
As many regenerative medicine and cell therapy products move into clinical trials, a clearer understanding of how these products will perform clinically is critical for achieving regulatory approval and ultimately, for commercialization. This session will discuss the major clinical events expected to drive the regenerative medicine sector over the next two years, as well as address some of the key issues facing these products as they approach the marketplace. Moderator: Greg Lucier, MBA, Chairman and CEO, Life Technologies Panelists: Jay Siegel, MD, Chief Biotechnology Officer and Head, Global Pharmaceutical Regulatory Affairs, Janssen Pharmaceutical Companies of Johnson Johnson Paul Simmons, Ph.D., Executive Vice President, Corporate Research and Product Development, Mesoblast Limited Matthias Steger, Ph.D., MBA, Global Head Research and Technology Partnering, Roche Ltd. Dean Tozer, Vice President, Corporate Development, Shire Regenerative MedicineFrom:AllianceRegenMedViews:5 1ratingsTime:01:16:22More inScience Technology

Read more:
SCMOM 2012_The Clinical Outlook for Regenerative Medicine - Video

Related Posts
This entry was posted in Cell Therapy. Bookmark the permalink.

Comments are closed.